

DAFTAR PUSTAKA

- Aeddula NR., Bardhan M., Baradhi KM, 2020. Sickle Cell Nephropathy. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jun 26, 2020.
- Al Saran K, Sabry A. The cost of hemodialysis in a large hemodialysis center. Saudi J Kidney Dis Transpl. 2012 Jan;23(1):78-82. PMID: 22237223.
- Amann K., Breitbart M., Ritz E., Mall G. 1998. Myocyte / capillary mismatch in the heart of uremic patients. *J Am Soc Nephrol*. 1998;9:1018–1022.
- Bello, A. K., Alrukhaimi, M., Ashuntantang, G. E., Basnet, S., Rotter, R. C., Douthat, W. G., Kazancioglu, R., Köttgen, A., Nangaku, M., Powe, N. R., White, S. L., Wheeler, D. C., & Moe, O. 2017. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. *Kidney international supplements*, 7(2), 122–129. doi: 10.1016/j.kisu.2017.07.007.
- Bento C., Fructuoso M., Costa R., Castro R., Morgado T. 2014. Very elderly patients on haemodialysis : evolution and its relation with comorbidities. *Port J Nephrol Hypertension*. 2014;28(4):325-329.
- Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases*, 40(5), 373–383. doi:10.1016/0021-9681(87)90171-8.
- Chertow GM., Burke SK., Raggi P., et al. 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int*. 2002;62:245–252
- Chisholm-Burns M.A., Schwinghammer T.L., Wells B.G., Malone P.M., Kolesar J.M. and DiPiro J.T. 2016. Pharmacotherapy Principles and Practice. Mc Graw-Hill Companies. New York.
- Dasari., Pranavi & Konuru., Venkateswarlu & Venisetty., Raj Kumar. 2014. Management of comorbidities in chronic kidney disease: A prospective observational study. *International Journal of Pharmacy and Pharmaceutical Sciences*. 6. 363-367.
- Dézi, C. A., & Szentes, V. 2017. The Real Role of β -Blockers in Daily Cardiovascular Therapy. *American journal of cardiovascular drugs : drugs, devices, and other interventions*, 17(5), 361–373. doi.:10.1007/s40256-017-0221-8.
- DiPiro J.T., Wells B.G., Schwinghammer T.L. and DiPiro C. V., 2015, Pharmacotherapy Handbook, Ninth Edit. McGraw-Hill Education Companies, Inggris.
- Doan, Q. V., Gleeson, M., Kim, J., Borker, R., Griffiths, R., & Dubois, R. W. 2007. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. *Current Medical Research and Opinion*, 23(7), 1561–1569. doi:10.1185/030079907x199790
- Fraser, S. D., Roderick, P. J., May, C. R., McIntyre, N., McIntyre, C., Fluck, R. J., Shardlow, A., & Taal, M. W. 2015. The burden of comorbidity in people

- with chronic kidney disease stage 3: a cohort study. *BMC nephrology*, 16, 193. doi: 10.1186/s12882-015-0189.
- Goldberg I., Krause I. 2016. The Role of Gender in Chronic Kidney Disease. *EMJ*.2016;1(2):58-64.
- Håheim LL., Fretheim A., Brørs O., Kjeldsen SE., Kristiansen IS., Madsen S., Njølstad ., Norheim OF., Ose L., Svilaas A. 2008. Primærforebygging av hjerte- og karsykdom, med hovedvekt på medikamentelle tiltak.
- Indonesian Renal Registry. 2018. *11th Report of Indonesian Renal Registry*.
- KDIGO. 2013. KDIGO 2012 *clinical practice guideline for the evaluation and management of chronic kidney disease*. ISN. 2013; 3(1):1–163.
- KDIGO. 2020. *Cardiovascular complications of chronic kidney disease: pioneering studies*.98. 522-566. doi: 10.1016/j.kint.2020.07.001.
- Kementrian Kesehatan RI. 2013. Pedomam Penerapan Kajian Farmakoekonomi 615.1 Ind p. ISBN 978-602-235-207-5. Jakarta.
- Kementrian Kesehatan RI. 2017. INFODATIN. *Pusat Data dan Informasi Kementrian Kesehatan RI Situasi Penyakit Ginjal Kronis*. Jakarta Selatan.
- Kerr, M., Bray, B., Medcalf, J., O'Donoghue, D. J., & Matthews, B. 2012. Estimating the financial cost of chronic kidney disease to the NHS in England. *Nephrology, dialysis, transplantation : official publication of the European dialysis and Transplant Association - European Renal Association*, 27 Suppl 3 (Suppl 3), iii73–iii80. doi: 10.1093/ndt/gfs269.
- Lee, W. C., Lee, Y. T., Li, L. C., Ng, H. Y., Kuo, W. H., Lin, P. T., Liao, Y. C., Chiou, T. T., & Lee, C. T. 2018. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease. *Journal of clinical medicine*, 7(12), 493. doi: 10.3390/jcm7120493.
- Martínez-Mesa, J., González-Chica, D. A., Duquia, R. P., Bonamigo, R. R., & Bastos, J. L. 2016. *Sampling: how to select participants in my research study?*. *Anais brasileiros de dermatologia*, 91(3), 326–330. <https://doi.org/10.1590/abd1806-4841.20165254>.
- Nitta K., Okada K., Yanai M., Takahashi S. 2013. Aging and chronic kidney disease. *Kidney Blood Press Res*. 2013;38(1):109-20. doi: 10.1159/000355760. Epub 2014 Mar 3. PMID: 24642796.
- Pourhoseingholi, M. A., Vahedi, M., & Rahimzadeh, M. 2013. Sample size calculation in medical studies. *Gastroenterology and hepatology from bed to bench*, 6(1), 14–17.
- Rostand SG, Gretes JC, Kirk KA, et al. 1979. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. *Kidney Int*. 1979;16:600– 611.
- Scher, H. E., Drew, M. L., & Cottrell, D. B. 2015. Treatment of Resistant Hypertension in the Patient With Chronic Kidney Disease. *The Journal for Nurse Practitioners*, 11(6), 597–604. doi:10.1016/j.nurpra.2015.03.018.
- Setia M. S. 2016. Methodology Series Module 5: Sampling Strategies. *Indian journal of dermatology*, 61(5), 505–509. doi: 10.4103/0019-5154.190118.
- Sumit Kumar, Ashish Baldi. 2013. Pharmacoeconomics: Principles, Methods and Economic Evaluation of Drug Therapies. Vol-2/Issue-5/Sept-Oct 2013.

- ISSN: 2278-1099. Department of Quality Assurance, I.S.F.College of Pharmacy, Moga, (Punjab), India.
- Thomas, R., Kanso, A., & Sedor, J. R. 2008. Chronic kidney disease and its complications. *Primary care*, 35(2), 329. doi: 10.1016/j.pop.2008.01.008.
- Unger T, Borghi C, Charchar F, et al. 2020. *International Society of Hypertension Global Hypertension Practice Guidelines*. doi:10.1161/HYPERTENSION.AHA.120.15026.
- Vaidya SR., Aeddula NR. 2020. Chronic Renal Failure. : StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan.
- Webster AC., Nagler EV., Morton RL., Masson P. 2017. Chronic Kidney Disease. *Lancet*. 2017 Mar 25;389(10075):1238-1252. [PubMed].
- Wisløff, T., Selmer, R. M., Halvorsen, S., Fretheim, A., Norheim, O. F., & Kristiansen, I. S. 2012. Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis. *BMC cardiovascular disorders*, 12, 26. doi: 10.1186/1471-2261-12-26.
- World Health Association. 2011. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for 2010.
- World Health Organization. 2020. Guidelines for ATC classification and DDD assignment 2020.
- World Health Organization. 2002. The World Health Report 2002: reducing risks, promoting healthy life. Geneva.
- Yang M., Fox CH., Vassalotti J., Choi M. 2011. Complications of progression of CKD. *Adv Chronic Kidney Dis*. 2011 Nov;18(6):400-5. doi:10.1053/j.ackd.2011.10.001. PMID: 22098657.
- Zhang, Y., He, D., Zhang, W., Xing, Y., Guo, Y., Wang, F., Jia, J., Yan, T., Liu, Y., & Lin, S. 2020. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. *Drugs*, 80(8), 797–811. <https://doi.org/10.1007/s40265-020-01290-3>.